LEXX
Lexaria Bioscience Corp.
NASDAQ · Healthcare · Biotechnology · CA
$14.15
+14.85%Sep 1, 2026, 13:15 UTC
Lexaria Bioscience Corp. received a cash rebate of AUD$3,666,611.98 (USD$2.6 million) from the Australian Tax Office, deposited into the account of its wholly-owned subsidiary Lexaria (AU) Pty Ltd.
Source:Aug 24, 2026, 13:10 UTC
Lexaria Bioscience announced completion of pharmacokinetic bioanalysis testing in its 2026 Animal Study #2, which evaluated oral delivery of amycretin and retatrutide using its DehydraTECH platform, showing significant absorption improvements.
Source:Aug 13, 2026, 13:00 UTC
Lexaria Bioscience Corp. entered into a Material Transfer Agreement with PegBio Co., Ltd to investigate Lexaria's DehydraTECH technology with a PegBio molecule under development for the GLP-1 industry.
Jun 25, 2026, 13:10 UTC
Lexaria Bioscience Corp. began dosing on schedule on June 14, 2026, for its Human Pilot Study #7 (GLP-1-H26-7) evaluating two oral DehydraTECH-semaglutide compositions against Novo Nordisk's Wegovy tablets.
Jun 23, 2026, 13:25 UTC
Lexaria Bioscience Corp. began dosing in its Animal Study #1 (GLP-1-A26-1) evaluating DehydraTECH-semaglutide and DehydraTECH-CBD compositions.
Source: